Business Context and Reporting Period
Company: Inspire Medical Systems, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 17, 2025
Event Date: November 6, 2025
Reporting Period: Fiscal Year 2025 (Fourth Quarter)
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific tax-related accounting event.
- Estimated Income Tax Benefit: $90 million to $100 million for fiscal year 2025.
- Impact on Diluted EPS: Expected increase of approximately $3.00 to $3.30 for fiscal year 2025.
Material Changes
The material change disclosed is the Company's expectation to release a significant portion of the valuation allowance on its U.S. deferred tax assets during the fourth quarter of fiscal 2025. This release is projected to generate a substantial non-operating income tax benefit.
Guidance, Outlook, and Risks
Management Commentary: The Company anticipates the tax benefit will materially improve diluted earnings per share for the year.
Risks and Uncertainties: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially from expectations due to risks and uncertainties discussed in other SEC filings. The Company undertakes no obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the final calculation of the valuation allowance release in the Q4 2025 earnings report.
- Confirm the actual impact on diluted earnings per share against the $3.00 to $3.30 estimate.
- Review the Company's other SEC filings for specific risk factors that could prevent the realization of this tax benefit.
- Assess whether this one-time tax benefit masks underlying operational performance trends.